Serke S, Huhn D
Virchow-Klinikum, Medizinische Fakultät, Humboldt-Universität zu Berlin, Germany.
Cytometry. 1996 Jun 15;26(2):154-60. doi: 10.1002/(SICI)1097-0320(19960615)26:2<154::AID-CYTO9>3.0.CO;2-G.
Peripheral blood samples from 115 consecutive patients and bone marrow samples from 9 healthy donors were studied for percentages of CD34-expressing cells, quantitative expression of various CD34 epitopes as defined by fluorescence mean channel, and mutual inhibition of the different CD34 monoclonal antibodies detecting the various CD34 epitopes. The study focused only on samples from patients with presumably elevated numbers of CD34-expressing cells, due to the nature of the disease. Samples from patients with chronic myeloproliferative syndromes, acute leukemias from nonhematological cancer patients during mobilization with filgrastim, and normal bone marrow samples were studied. Elevated numbers of CD34-expressing cells (> 0.04% of all nucleated cells) were detected in 111 of 124 patients. An almost identical expression of CD34 epitopes as detected by phycoerythrin-conjugated monoclonal antibodies QBEND-10, 8G12, and ICH3 were detected, whereas expression of the IMMU409 epitope was detected in only a few samples (19 of 111). Reactivity of IMMU-133 was almost identical to that of QBEND-10. Reactivity of BIRMA-K3, the only CD34 monoclonal used in this study, but not described in previous workshops, was almost identical to that of 8G12. From studies on mutual inhibition of binding, two families of CD34 epitopes are defined. The first family is comprised of QBEND-10, IMMU-133, My-10, and ICH-3, and the second one is comprised of only 8G12 and BIRMA-K3.
对115例连续患者的外周血样本和9例健康供者的骨髓样本进行了研究，以检测表达CD34的细胞百分比、荧光平均通道所定义的各种CD34表位的定量表达，以及检测各种CD34表位的不同CD34单克隆抗体之间的相互抑制作用。由于疾病的性质，该研究仅关注推测表达CD34的细胞数量升高的患者样本。研究了慢性骨髓增殖性综合征患者、非血液系统癌症患者在使用非格司亭动员期间的急性白血病患者以及正常骨髓样本。在124例患者中的111例检测到表达CD34的细胞数量升高（>所有有核细胞的0.04%）。检测到藻红蛋白偶联的单克隆抗体QBEND-10、8G12和ICH3所检测的CD34表位表达几乎相同，而仅在少数样本（111例中的19例）中检测到IMMU409表位的表达。IMMU-133的反应性与QBEND-10几乎相同。本研究中使用的唯一一种CD34单克隆抗体BIRMA-K3（但在以往研讨会上未描述）的反应性与8G12几乎相同。通过结合相互抑制研究，定义了两个CD34表位家族。第一个家族由QBEND-10、IMMU-133、My-10和ICH-3组成，第二个家族仅由8G12和BIRMA-K3组成。
